Translation of molecular pathways into clinical trials of neuroendocrine tumors

Neuroendocrinology

Volumn 97, Issue 1, 2013, Pages 99-112

  Pavel, Marianne ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Carcinoid; Neuroendocrine tumors; Signaling pathways; Targeted drugs; Targets

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; AXITINIB; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR; GEFITINIB; INTERFERON RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; OCTREOTIDE; PANITUMUMAB; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; SOMATOMEDIN C RECEPTOR; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SORAFENIB; SUNITINIB; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VATALANIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; DOPAMINE RECEPTOR; ENZYME; OXALIPLATIN; PASIREOTIDE; PROTEASOME; STAT3 PROTEIN; TELOTRISTAT ETHYL; TEMOZOLOMIDE; TRYPTOPHAN HYDROXYLASE;

ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ASTHENIA; CANCER SURVIVAL; CARCINOID; CARCINOID SYNDROME; CELL PROLIFERATION; CELL SURVIVAL; DIARRHEA; DRUG MECHANISM; DRUG TARGETING; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOPHYSIS ADENOMA; INSULINOMA; MOLECULARLY TARGETED THERAPY; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; NONHUMAN; PANCREATIC NEUROENDOCRINE TUMOR; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; REVIEW; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; STOMATITIS; SYMPTOMATOLOGY; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; VOMITING; ANGIOGENESIS; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER THERAPY; CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; CARCINOMA, NEUROENDOCRINE; PROCEDURES; TRANSLATIONAL RESEARCH; TRENDS;

ANTINEOPLASTIC AGENTS; CARCINOMA, NEUROENDOCRINE; CLINICAL TRIALS AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84874111766     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000336089     Document Type: Review

References (97)

1. Öberg K, Eriksson B: The role of interferons in the management of carcinoid tumors. Acta Oncol 1991; 30519-522.
2. Eriksson B, Klöppel G, Krenning E, et al: Consensus guidelines for the management of patients with digestive neuroendocrine tumors-well- differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 2008; 87: 8-19.
3. Modlin IM, Pavel ME, Kidd M, Gustafsson B: Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumors. Aliment Pharmacol Ther 2010; 31: 169-188.
4. Rinke A, Müller H, Schade-Brittinger C, et al: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumour growth in patients with metastatic neuroen-docrine midgut tumours: a report from the PROMID Study Group. J Clin Oncol 2009; 28:4656-4663.
5. Sun W, Lipsitz S, Catalano P, et al: Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluoroura-cil or dacarbazine in the treatment of advanced carcinoid tumours: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005; 23: 4897-4904.
6. Vilar E, Salazar R, Pérez-García J, et al: Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer 2007; 14: 221-232.
7. Christofori G, Naik P, Hanahan D: Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumor-igenesis. Mol Endocrinol 1995; 9: 1760-1770.
8. Inoue M, Hager JH, Ferrara N, et al: VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic fS-cell carcinogenesis. Cancer Cell 2002; 1: 193-202.
9. Fjällskog ML, Lejonklou MH, Oberg KE, et al: Expression of molecular targets for tyro-sine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 2003; 9: 1469-1473.
10. Von Wichert G, Jehle PM, Hoeflich A, et al: Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res 2000; 60:4573-4581.
11. Höpfner M, Sutter AP, Gerst B, Zeitz M, Scherübl H: A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839). Br J Cancer 2003; 89:1766-1775.
12. Nolan-Stevaux O, Truitt MC, Pahler JC, et al: Differential contribution to neuroendocrine tumorigenesis of parallel EGFR signaling in cancer cells and pericytes. Genes Cancer 2010; 1:125-141.
13. Pietras K, Hanahan D: A multitargeted, metronomic, and maximum-tolerated dose 'chemo-switch' regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005; 23: 939-952.
14. Chiu CW, Nozawa H, Hanahan D: Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carci-nogenesis. J Clin Oncol 2010; 28:4425-4433.
15. Kharmate G, Rajput PS, Watt HL, Somvanshi RK, Chaudhari N, Qiu X, Kumar U: Role of somatostatin receptor 1 and 5 on epidermal growth factor receptor mediated signaling. Biochim Biophys Acta 2011; 1813:1172-1189.
16. Jiao Y, Shi C, Edil BH, et al: DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendo-crine tumors. Science 2011; 331: 1199-1203.
17. Nasir A, Stridsberg M, Strosberg J, et al: So-matostatin receptor profiling in hepatic me-tastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohisto-chemical approach with potential clinical utility. Cancer Control 2006; 13: 52-60.
18. John M, Meyerhof W, Richter D, et al: Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut 1996; 38:33-39.
19. Kulaksiz H, Eissele R, Rössler D, et al: Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype-specific antibodies. Gut 2002; 50:52-60.
20. Patel YC: Molecular pharmacology of so-matostatin receptor subtypes. J Endocrinol Invest 1997; 20:348-367.
21. Fjällskog ML, Ludvigsen E, Stridsberg M, Oberg K, Eriksson B, Janson ET: Expression of somatostatin receptor subtypes 1-5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. Med Oncol 2003; 20: 59-67.
22. Cakir M, Dworakowska D, Grossman A: So-matostatin receptor biology in neuroendo-crine and pituitary tumours: part 1-molecular pathways. J Cell Mol Med 2010: 2570-2584.
23. Pyronnet S, Bousquet C, Najib S, Azar R, Laklai H, Susini C: Antitumor effects of so-matostatin. Mol Cell Endocrinol 2008; 286: 230-237.
24. Shah T, Caplin M: Endocrine tumours of the gastrointestinal tract. Biotherapy for meta-static endocrine tumours. Best Pract Res Clin Gastroenterol 2005; 19: 617-636.
25. Schmid HA: Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol 2008; 286: 69-74.
26. Bruns C, Lewis I, Briner U, et al: SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002; 146:707-716.
27. Feelders RA, de Bruin C, Pereira AM, et al: Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N Engl J Med 2010; 362:1846-1848.
28. Kvols L, Wiedenmann B, Oberg K, et al: The SOM230 Carcinoid Study Group 2006: safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: results of a phase II study. J Clin Oncol 2006; 24: 198s.
29. Fedele M, De Martino I, Pivonello R, et al: SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hor-mone/prolactin- secreting pituitary adenomas. Clin Cancer Res 2007; 13: 2738-2744.
30. Kidd M, Schally AV, Pfragner R, Malfert-heiner M V, Modlin IM: Inhibition of proliferation of small intestinal and bronchopul-monary neuroendocrine cell lines by using peptide analogs targeting receptors. Cancer 2008; 112:1404-1414.
31. Ginj M, Zhang H, Waser B, et al: Radiola-beled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA 2006; 103:16436-16441.
32. Srirajaskanthan R, Watkins J, Marelli L, Khan K, Caplin M: Expression of somato-statin and dopamine-2 receptors in neuro-endocrine tumours and the potential role for new biotherapies. Neuroendocrinology 2009; 89:308-314.
33. O'Toole D, Saveanu A, Couvelard A, et al: The a nalysis of qua nt itat ive ex pression of so-matostatin and dopamine receptors in gas-tro-entero- pancreatic tumours opens new therapeutic strategies. Eur J Endocrinol 2006; 155:849-857.
34. Jaquet P, Gunz G, Saveanu A, et al: BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, versus universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J Endocri-nol Invest. 2005; 28(suppl int):21-27.
35. Culler MD: Somatostatin-dopamine chimeras: a novel approach to treatment of neuroendocrine tumors. Horm Metab Res 2011; 43: 854-857.
36. Kidd M, Drozdov I, Joseph R, et al: Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. Cancer 2008; 113: 690-700.
37. Platanias LC: Mechanisms of type-I-and type-II-interferon-mediated signaling. Nat Rev Immunol 2005; 5: 375-386.
38. Öberg K: Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion 2000; 62(suppl 1):92-97.
39. Faiss S, Pape U, Böhmig M: Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancre-atic tumors-the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003; 21:2689-2696.
40. Dahan L, Bonnetain F, Rougier P, et al: Phase III trial of chemotherapy using 5-fluoroura-cil and streptozotocin compared with inter-feron-a for advanced carcinoid tumors: FNCLCC-FFCD 9710. Endocr Relat Cancer 2009; 16: 1351-1361.
41. Welin S, Fjällskog ML, Saras J, Eriksson B, Janson ET: Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors. Neuroendocrinology 2006; 84:42-48.
42. Fjällskog ML, Hessman O, Eriksson B, Janson ET: Upregulated expression of PDGF receptor p in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas. Acta Oncol 2007; 46:741-746.
43. Couvelard A, O'Toole D, Turley H, et al: Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer 2005; 92:94-101.
44. Zhang J, Jia Z, Li Q, et al: Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 2007; 109:1478-1486.
45. Von Marschall Z, Scholz A, Cramer T, et al: Effects of interferon-a on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Nat Cancer Inst 2003; 95: 437-448.
46. Bergers G, Song S, Meyer-Morse N, Bergs-land E, Hanahan D: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111:1287-1295.
47. Pietras K, Hanahan D: A multitargeted, metronomic, and maximum-tolerated dose 'chemo-switch' regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 2005; 23: 939-952.
48. Kulke MH, Bergsland EK, Ryan DP, et al: Phase II study of recombinant human end-ostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 2006; 24: 3555-3561.
49. Varker KA, Campbell J, Shah MH: Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother Pharmacol 2008; 61: 661-668.
50. 2b. J Clin Oncol 2008; 26: 1316-1323.
51. Kulke M, Stuart K, Earle C, et al: A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. ASCO Annual Meeting Proceedings, Part I. J Clin Oncol 2006; 24(suppl):abstr 4044.
52. Kunz P, Kuo T, Zahn J, et al: A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors. J Clin Oncol 2010; 28(suppl):abstr 4104.
53. Castellano D, Capdevila J, Salazar R, et al: Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: a phase II study of the Spanish Neuroendocrine Tumor Group (GETNE0801). J Clin Oncol 2011; 29(suppl):abstr 4113.
54. Faivre S, Demetri G, Sargent W, Raymond E: Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007; 6:734-745.
55. Chow LQ, Eckhardt S: Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007; 25:884-896.
56. Kulke MH, Lenz HJ, Meropol NJ, et al: Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26: 3403-3410.
57. Raymond E, Dahan L, Raoul J-L, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:501-513.
58. Raymond E, Niccoli P, Raoul J, et al: Updated overall survival and progression-free survival by blinded independent central review of sunitinib versus placebo for patients with advanced unresectable pancreatic neuroendocrine tumors. J Clin Oncol 2011; 29(suppl): abstr 4008.
59. Pavel ME, Bartel C, Heuck F, et al: Open-label, non-randomized, multicenter phase II study evaluating the angiogenesis inhibitor PTK787/ZK222584 in patients with advanced neuroendocrine carcinomas. J Clin Oncol 2008; 26(suppl):abstr 14684.
60. Hobday T, Rubin J, Holen K: MCO44h, a phase II trial of sorafenib in patients with metastatic neuroendocrine tumours: a phase II consortium (P2C) study. J Clin Oncol 2007; 25(suppl):4504.
61. Phan A, Yao J, Fogelman D, Hess KR, et al: A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). J Clin Oncol 2010; 28(suppl):abstr 4001.
62. Meric-Bernstam F, Gonzalez-Angulo AM: Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009; 27:2278-2287.
63. Missiaglia E, Dalai I, Barbi S, et al: Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010; 28:245-255.
64. Kasajima A, Pavel M, Darb-Esfahani S, et al: mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2011; 18: 181-192.
65. Zitzmann K, Rüden J, Brand S, et al: Compensatory activation of Akt in response to mTOR and Raf inhibitors-a rationale for dual-targeted therapy approaches in neuro-endocrine tumor disease. Cancer Lett 2011; 295:100-109.
66. Svejda B, Kidd M, Kazberouk A, et al: Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT. Cancer 2011; 117: 4141-4154.
67. Duran I, Kortmansky J, Singh D, et al: A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroen-docrine carcinomas. Br J Cancer 2006; 95: 1148-1154.
68. Yao JC, Phan AT, Chang DZ, et al: Efficacy of R AD001 (everolimus) and octreotide LAR i n advanced low-to i nter mediate-g rade neu-roendocrine tumors: results of a phase II study. J Clin Oncol 2008; 26: 4311-4318.
69. Yao JC, Lombard-Bohas C, Baudin E, et al: Daily oral everolimus activity in patients wit h metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II tria l. J Clin Oncol 2010; 28: 69-76.
70. Yao JC, Shah MH, Ito T, et al: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011, 364: 514-523.
71. De Vries E, Anthony L, Sideris L, et al: Effect of everolimus treatment on chromogranin A, neuron-specific enolase, gastrin, and glu-cagon levels in patients with advanced pancreatic neuroendocrine tumors: phase III RADIANT-3 study results. J Clin Oncol 2011; 29(suppl);abstr 10624.
72. Kulke M, Bergsland E, Yao J: Glycemic control in patients wit h insu linoma treated with everolimus. N Engl J Med 2009; 360: 195-197.
73. Pavel M, Hainsworth JD, Baudin E, et al: Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011;378:2005-2012.
74. Kulke M, Blaszkowsky L, Zhu A: Phase I/II study of everolimus (RAD001) in combination with temozolomide in patients with advanced pancreatic neuroendocrine tumors. Gastrointestinal Cancers Symposium 2010, abstr 223.
75. Yao J, Phan A, Fogleman D, et al: Randomized run-in study of bevacizumab and evero-limus in low-to intermediate-grade neuro-endocrine tumors using perfusion CT as functional biomarker. J Clin Oncol 2010; 28(suppl):abstr 4002.
76. Wulbrand U, Wied M, Zöfel P, Göke B, Arnold R, Fehmann H: Growth factor receptor expression in human gastroenteropancre-atic neuroendocrine tumours. Eur J Clin Invest 1998; 28:1038-1049.
77. Von Wichert G, Jehle PM, Hoeflich A, et al: Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res 2000; 60:4573-4581.
78. Tolcher AW, Sarantopoulos J, Patnaik A, et al: Phase I, pharmacokinetic, and pharmaco-dynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009; 27: 5800-5807.
79. Reidy DL, Hollywood E, Segal M, Saltz L: A phase II clinical trial of MK-0646, an insulin-like growth factor-1 receptor inhibitor, in patients with metastatic well-differentiated neuroendocrine tumors. J Clin Oncol 2010; 28(suppl):abstr 4163.
80. Ulanet DB, Ludwig DL, Kahn CR, Hanahan D: Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci USA 2010; 107:10791-10798.
81. Holbro T, Civenni G, Hynes NE: The ErbB receptors and their role in cancer progression. Exp Cell Res 2003; 284: 99-110.
82. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al: Epidermal growth factor receptor signaling in cancer. Gene 2006; 366:2-16.
83. Gilbert JA, Adhikari LJ, Lloyd RV, et al: Molecular markers for novel therapies in neuro-endocrine (carcinoid) tumors. Endocr Relat Cancer 2010; 17: 623-636.
84. Papouchado B, Erickson LA, Rohlinger AL, et al: Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol 2005; 18: 1329-1335.
85. Bergmann F, Breinig M, Höpfner M, et al: Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors? Am J Gastroenterol 2009; 104: 171-181.
86. Srirajaskanthan R, Shah T, Watkins J, Marel-li L, Khan K, Caplin ME: Expression of the HER-1-4 family of receptor tyrosine kinases in neuroendocrine tumours. Oncol Rep 2010; 23: 909-915.
87. Hobday TJ, Holen K, Donehower R, et al: A phase II trial of gefitinib in patients with progressive metastatic neuroendocrine tumors: a phase II consortium (P2C) study. J Clin Oncol 2006; 24(suppl):abstr 4043.
88. Kulke M, O'Dorisio TM, Phan AT, et al: A phase II, multicenter, randomized, double-blind, placebo-controlled, ascending, multi-dose, US study of oral LX1606 (aka LX1032) in patients with refractory symptomatic carcinoid syndrome. J Clin Oncol 2011; 29(suppl):abstr TPS168.
89. Chen JY, Cook MR, Pinchot SN, Kunnima-laiyaan M, Chen H: MG-132 inhibits carci-noid growth and alters the neuroendocrine phenotype. J Surg Res 2010; 158:15-19.
90. Shah MH, Young D, Kindler HL, Webb I, Kleiber B, Wright J, Grever M: Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendo-crine tumors. Clin Cancer Res 2004; 10: 6111-6118.l
91. Zhao M, Jiang B, Gao FH: Small molecule inhibitors of STAT3 for cancer therapy. Curr Med Chem 2011; 18: 4012-4018.
92. Sung M, Kvols L, Wolin E, et al: Phase II proof-of-concept study of atiprimod in patients with advanced low-to intermediate-grade neuroendocrine carcinoma. J Clin Oncol 2008; 26(suppl):abstr 4611.
93. Serra V, Markman B, Scaltriti M, et al: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008; 68:8022-8030.
94. Engelman JA, Chen L, Tan X, et al: Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R mu-rine lung cancers. Nat Med 2008; 14:1351-1356.
95. Schnell CR, Stauffer F, Allegrini PR, et al: Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res 2008; 68:6598-6607.
96. Detjen KM, Rieke S, Deters A, et al: Angio-poietin-2 promotes disease progression of neuroendocrine tumors. Clin Cancer Res 2010; 16:420-429.
97. Robson EJ, Ghatage P: AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer. Expert Opin Investig Drugs 2011; 20:297-304.